Helus Pharma
Toronto · Founded 2019
About Helus Pharma
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube, and Instagram.
Company Facts
- Founded: 2019
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $572.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: tsx:HELP
- Website: https://www.helus.com/
- Phone: +1 908-764-8385
Industries & Categories
Biotechnology, Health Care, Mental Health, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/helus-pharma-16059 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.